New drug cocktail aims to fight esophageal cancer when immunotherapy fails
NCT ID NCT06339619
First seen Jun 12, 2026 · Last updated Jun 22, 2026 · Updated 2 times
Summary
This phase 2 trial is testing a combination of three drugs—adebrelimab (immunotherapy), apatinib (targeted therapy), and tegafur (chemotherapy)—in 32 people with advanced esophageal cancer that stopped responding to initial immunotherapy plus chemotherapy. The main goal is to see how many patients' tumors shrink or disappear. Researchers will also track how long patients live without the cancer growing and any serious side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED OR METASTATIC ESOPHAGEAL SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
RECRUITINGGuangzhou, Guangdong, 510030, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
adebrelimab (an immunotherapy drug), apatinib (a targeted therapy), and tegafur (a chemotherapy drug)
What this could lead to
If successful, this combination could offer a new treatment option for people with advanced esophageal cancer whose first immunotherapy stopped working.
What could go wrong
This is a small, early-phase trial with only 32 participants, so results may not apply to everyone. The drugs can cause serious side effects, and there is no guarantee the combination will work better than existing options.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.